Raze Therapeutics Announces Addition of Julian Adams, PhD, George Q. Daley, MD, PhD, and Karen Vousden, PhD, to Scientific Advisory Board

Raze Therapeutics, a leading next generation cancer metabolism company, announced today the expansion of its Scientific Advisory Board (SAB) with the addition of three leaders in oncology drug discovery and development.

Press Release

back to overview